Evidence map›Paper›PMID 31308743›Full record

ArticleCancer management and research2019

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy" method.

Yizhao Xie, Bingxin Gu, Xichun Hu, Yingjian Zhang, Jian Zhang, Zhonghua Wang, Yannan Zhao, Chengcheng Gong, Yi Li, Zhongyi Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Heterogeneity derived fromCancer medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yizhao Xie *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Bingxin Gu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yingjian ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Jian ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Zhonghua WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yannan ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Chengcheng GongDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yi LiDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Zhongyi YangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Biyun WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chemotherapyPETtriple-negative breast cancertumor heterogeneity

Identifiers

PMID31308743
PMCPMC6612961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.